Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sube Banerjee

Showing results (191-200 of 214) with videos related to

Pageof 22
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Age and Ageing|April 21, 2024
Feasibility and acceptability of NIDUS-professional, a training and support intervention for homecare workers caring for clients living with dementia: a cluster-randomised feasibility trialClaudia Cooper, Sedigheh Zabihi, Amirah Akhtar, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Age and Ageing|March 21, 2025
Process evaluation in a randomised controlled trial of DREAMS-START (dementia related manual for sleep; strategies for relatives) for sleep disturbance in people with dementia and their carersSarah Amador, Gill Livingston, Mariam Adeleke, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
Lancet (London, England)|July 25, 2017
Dementia prevention, intervention, and careGill Livingston, Andrew Sommerlad, Vasiliki Orgeta, et al.
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Pageof 22

Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Age and Ageing|April 21, 2024
Feasibility and acceptability of NIDUS-professional, a training and support intervention for homecare workers caring for clients living with dementia: a cluster-randomised feasibility trialClaudia Cooper, Sedigheh Zabihi, Amirah Akhtar, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Age and Ageing|March 21, 2025
Process evaluation in a randomised controlled trial of DREAMS-START (dementia related manual for sleep; strategies for relatives) for sleep disturbance in people with dementia and their carersSarah Amador, Gill Livingston, Mariam Adeleke, et al.
Lancet (London, England)|July 19, 2011
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialSube Banerjee, Jennifer Hellier, Michael Dewey, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
Lancet (London, England)|July 25, 2017
Dementia prevention, intervention, and careGill Livingston, Andrew Sommerlad, Vasiliki Orgeta, et al.
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Pageof 22